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Alzheimer’s disease is a devastating neurodegenerative condition currently aﬀecting over 5 million elderly individuals in the
United States. There is much evidence suggesting that certain dietary lifestyles can help to prevent and possibly treat Alzheimer’s
disease. In this paper, we discuss how certain cardiovascular and diabetic conditions can induce an increased susceptibility for
Alzheimer’s disease and the mechanisms through which this occurs. We further discuss how the consumption of certain foods or
food components can help to reduce one’s risk for Alzheimer’s disease and may possibly be developed as a therapeutic agent.
1.Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder characterized by a progressive decline in memory
functions, which has become a growing public health con-
cern. This condition of clinical dementia was ﬁrst described
by Alois Alzheimer in 1907, and ever since, the incidence of
ADhasincreasedexponentially.Therearepresently5million
AmericansaﬀectedwithAD,andtheestimatedannualhealth
care cost is almost 100 billion dollars. Further, due to the
expected increase in the number of individuals 65 years or
older, it has been estimated that the total incidence of AD
will quadruple by the year 2050 [1].
As there is presently no cure for this devastating condi-
tion, there is an urgent need to ﬁnd a means of preventing,
delaying the onset, or reversing the course of AD. Recent
research has provided evidence that certain dietary lifestyle
choices can help to prevent Alzheimer’s disease. This area of
research has been quite exciting in light of the fact that de-
laying the onset of AD by just ﬁve years could cut its inci-
dence in half.
In this paper, we ﬁrst discuss the major pathological
featuresofADclinicaldementia,followedbyanexamination
of research on certain dietary factors that have been found to
inﬂuence AD. These dietary factors include calorie, fat, and
glucose/sugarintake,inadditiontotheinclusionoffoodslike
ﬁsh, certain fruits and vegetables, plant extracts, spices and
red wine, or polyphenol-rich foods in one’s diet.
AD is pathologically characterized by the depositions of
beta-amyloid aggregates in extracellular spaces and cerebral
vasculatures as well as intracellular depositions of aggregated
tau protein [2]. The “amyloid cascade hypothesis” is a pop-
ular model of AD pathogenesis and most of the autosomal
dominant familial AD cases are caused by mutations in the
amyloid precursor protein (APP), presenilin 1, or presenilin
2, which lead to increased generation of beta-amyloid (Aβ)
peptides.However,themajorityoftheADcasesaresporadic.
Cause(s) of sporadic AD are largely unknown. Multiple risk
factors may contribute to the onset of sporadic AD. These
riskfactorsincludegeneticriskfactorsuchastheapolipopro-
tein E (APOE) genotype, as well as nongenetic and envi-
ronmentally modiﬁable factors, including dietary, cardio-
vascular risk factors, physical and intellectual activities,
and environment factors. As such, these factors have been
generally considered as potential targets of intervention for
AD prevention and therapy.
1.1.Alzheimer’sDiseaseNeuropathology. ADischaracterized
in the brain by accumulated extracellular β-amyloid (Aβ)
plaquesandintracellularneuroﬁbrillarytanglescomposedof2 International Journal of Alzheimer’s Disease
abnormallyhyperphosphorylatedmicrotubulartauproteins.
The manifestation of AD clinically is a progressive loss of
cognitive abilities, including deﬁcits in memory and plan-
ning. Neurotoxic Aβ is known to exist in multiple assembly
states, which often result in varying pathophysiological ef-
fects. Additionally, although Aβ is classically understood to
be deposited extracellularly, there is new evidence in mice
and humans that Aβ peptides can also accumulate intraneu-
ronally [3]. Aβ species are generated from the ubiquitously
expressed amyloid precursor protein (APP) through sequen-
tial proteolysis by β-a n dγ-secretases [4–6]. Although the
40-amino acid form of Aβ (Aβ1–40) is considered to be the
major secreted species in AD, the 42-amino acid form of Aβ
(Aβ1–42), which contains two additional residues at its car-
boxylterminus,isthoughttoinitiateADpathogenesis[7].In
addition, tau proteins in the brain (most particularly hyper-
phosphorylated tau), which aggregate into paired helical
ﬁlaments and deposit as intracellular neuroﬁbrillary tangles,
[8, 9], are also considered to be a major pathology associated
with Alzheimer’s disease. Researchers posit that abnormal
hyperphosphorylation of tau leads to the sequestration of
normal and hyperphosphorylated tau in microtubules, lead-
ing to alternations in the healthy functioning of tau in the
brain (including changes in axon transport and microtubule
stability and polymerization [10, 11]). As Aβ species and
tau neuroﬁbrillary tangles are the major hallmarks of AD
neuropathology, research on therapies or preventions for
AD are often geared toward attenuating or treating these
neuropathologies.
In addition to Aβ and tau pathologies, mitochondrial
functions also play a major role in AD clinical dementia
[12]. Mitochondria regulate energy metabolism in cells and
contribute largely to cell life or death (apoptosis). In the
presence of increased Aβ content in the brain, mitochon-
dria increase the generation of reactive oxygen species
(ROS), which function as damaging agents and as signaling
molecules. Highly reactive ROS, in fact, unleash a mecha-
nism involving the liberation of cytochrome c, leading to
neuronal apoptosis [13, 14]. In human AD patients, positron
emission tomography (PET) imaging assessments have sug-
gested that the AD brain is characterized by impaired mi-
tochondrial glucose metabolism, leading to neuronal hyper-
glycemic conditions [15]. In light of this evidence, control-
ling mitochondrial glucose/energy metabolism in the brain
has also been of high interest to AD researchers for the
prevention and treatment of AD.
2.Obesityandthe Metabolic Syndrome inAD
High-fat diets and sedentary lifestyles have become major
concerns throughout the world. They have led to a growing
incidence of obesity, dyslipidemia, high blood pressure, and
hyperglycemic conditions, known collectively to be compo-
nents of metabolic syndrome [16]. These health conditions
are well known to develop along with, or be precursors of,
atherosclerosis, cardiovascular disease, and diabetes. Recent
studies have found that most of these disorders can also be
linked to an increased risk of AD. Of note, accumulating
evidence suggests a mechanistic link between cholesterol
metabolism in the brain and the formation of amyloid pla-
ques in AD development [17, 18].
Epidemiological studies have demonstrated that individ-
uals with obesity and diabetes have a fourfold increased
risk for AD. Health risks associated with obesity, including
evidence that obesity may causally promote the AD degen-
erative process, are of high concern for public health. By the
beginning of the twenty-ﬁrst century, the fraction of Amer-
icans considered to be obese reached “epidemic” levels,
accordingtoastudypublishedin[19].Thisstudy,carriedout
between 1991 and 1998, observed a steady increase in weight
in all 50 states, across genders, age groups, races, and educa-
tionallevels,andoccurringregardlessofsmokingstatus.This
study found that obesity had increased from 12.0% in 1991
to 17.9% in 1998. Likewise, national survey data has shown
that between 1976–1980 and 1988–1994, the age-adjusted
prevalence of obesity increased by 8 percentage points, from
14.5% to 22.5%, in the US adult population ages 20–74 years
[20].
Several major studies have been conducted in humans
to explore the relationship between obesity and the brain.
Recently, Pannacciulli and colleagues [21] explored the as-
sociation between body fat and regional alterations in brain
structure using voxel-based morphometry (VBM) imaging
(based on high-deﬁnition 3D magnetic resonance imaging
[MRI]). Compared to lean subjects, obese individuals were
found to have signiﬁcantly lower gray matter density in the
postcentral gyrus, frontal operculum, putamen, and middle
frontal gyrus, indicating diﬀerences in the brain regulation
of taste, reward and behavioral control. Additionally, Whit-
mer and colleagues [22] evaluated the possible association
between obesity (as measured by body mass index (BMI)
and skinfold thickness) in middle age and risk of dementia
in later life in a large scale, multiethnic population-based co-
hort. Findings revealed that obese individuals (BMI > 30) in
middle age had a 35% higher risk for dementia compared to
normal weight individuals (18.6 < BMI < 24.9), independent
of other comorbid conditions. Additionally, Balakrishnan
and colleagues [23] investigated the association between
blood plasma Aβ levels (which promote AD development),
BMI, and fat mass (FM) in healthy adults and found
signiﬁcant correlations of BMI and FM with plasma Aβ1–42
levels and also noted that the presence of certain proteins
knowntoplayaroleininﬂammation,cardiovasculardisease,
and type 2 diabetes strengthened these correlations.
Researchers have also investigated the role of leptin, a
protein hormone secreted in fat cells associated with obesity
(which regulates appetite and metabolism), in AD pathogen-
esis. In pathological conditions of aging, such as in AD, it
has been demonstrated that the transport of leptin across
the blood brain barrier (BBB) is signiﬁcantly impaired, in
particular, by the downregulation of megalin, a protein to
which leptin must bind in order to enter the brain [24].
Leptin has also been shown to reduce β-secretase activity in
neuronal cells, possibly by altering the lipid composition of
membranerafts,andtherebyaﬀectingAβ generation.Infact,
chronic administration of leptin actually reduced Aβ load in
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of leptin as a treatment for AD [25] and providing further
support for the hypothesized link between obesity and AD.
3.Calo rieI ntak eandCalo ricR estrictio n
Research has demonstrated that caloric intake (among other
nongenetic factors) inﬂuences one’s risk for AD, and, ac-
cordingly, that curbing obesity/calorie intake might play an
importantroleindelayingtheADdegenerativeprocess.Clar-
ifying the mechanisms through which caloric intake may
ultimately inﬂuence AD neuropathology, and how caloric
restriction (CR) may exert anti-β-amyloidogenic activities,
may provide new avenues for designing preventive and/or
therapeutic lifestyle strategies for AD and other neurodegen-
erative conditions.
The hypothesized preventive eﬀects of CR on the de-
velopment of mild cognitive impairment (MCI) or AD are
supported by epidemiological evidence indicating that indi-
viduals who habitually consume fewer calories have a re-
duced incidence of AD [26, 27]. Additionally, studies have
demonstrated that CR is one method by which one can
mitigate the risk factor presented by elevated plasma homo-
cysteine levels (which increase with age) for AD. Speciﬁcally,
as high homocysteine levels render neurons to be more vul-
nerable by impairing DNA repair mechanisms (and thereby
promotingcelldeath),loweringhomocysteinelevelsthrough
CR could potentially help to maintain the brain’s neuropro-
tective abilities and help prevent against AD [28].
Halagappa and colleagues [29] tested the hypothesis
that two diﬀerent dietary energy restriction regimens—40%
calorie restriction (CR) and intermittent fasting (IF)—could
protectagainstcognitivedeclineinatransgenicmousemodel
of AD and found that both regimens ameliorated age-
related cognitive impairments but could not directly link the
observed eﬀects to Aβ and tau pathologies. Further, Wu and
colleagues[30]investigatedtheeﬀectsofCRfor4monthson
diﬀerent AD phenotypes in another mouse model, ﬁnding
that CR diets improved cognitive impairments in treated
mice based on improved scores on assessments of novel
objectrecognitionandcontextualfearconditioningmemory.
Further histological and biochemical analyses revealed that
CR actually attenuated ventricle enlargement, caspace-3 ac-
tivation and astrogliosis and reduced the induction of tau
hyperphosphorylation. Importantly, DNA microarray anal-
ysis in this study also demonstrated that CR could increase
the expression of neurogenesis-related genes and decrease
the expression of inﬂammation-related genes in the hip-
pocampus of the mice, indicating that CR could induce
neuroprotective activity in the brain.
In accordance with this line of work, we initiated a series
of studies to investigate whether AD pathogenesis can be
prevented by reducing calorie intake to levels appropriate for
cardiac health. At the beginning of this endeavor, although
evidence had supported a possible neuroprotective role of
CR in neurodegeneration, there had been no information
regarding whether CR could attenuate AD neuropathology
until recently.
We explored whether a clinically acceptable weight
reduction/CR regimen, based on an approximately 30%-
reduced carbohydrate intake, could attenuate AD neuropa-
thology and possibly mitigate preexisting amyloid neuritic
pathology (by a reduction in plaque size) resulting in the
recovery of amyloid-associated neuritic dystrophy as a func-
tion of time in Tg2576 AD-type mice [31]. In this study
[32], 3-month old Tg2576 mice, which developed AD-type
amyloid neuropathology at 8–10 months of age, were fed
with a daily low-carbohydrate (low-carb) diet for 9 months,
resulting in 30% lower caloric intake compared to age- and
gender-matched control mice fed ad libitum (AL) with a
standard laboratory rodent diet (dietary content of protein,
fat, cholesterol, vitamins, and minerals were identical across
both mice groups). We found that the low-carb/CR diet
in mice resulted in body weight stabilization, 3-fold lower
ependymal fat pad weight, and improved glucose tolerance
responses compared to the AL-fed mice at 9 months of
age. This ﬁnding was consistent with clinical evidence
indication that low-carb/CR diets considerably improve ab-
normal glucose control and obesity [33–35], which are risk
factors for diabetes and AD [27, 36]. Moreover, when ex-
amined for AD-type neuropathology, we found that the CR
intervention almost completely prevented cortical and hip-
pocampal AD-type amyloid plaque (lower Aβ1–40 and Aβ1–42
concentrations) development relative to the AL-fed group.
We next proceeded to explore APP processing and Aβ
peptide generation in the CR- and AL-fed mice, and, con-
sistent with our previous evidence, we conﬁrmed decreased
levels of Aβ1–40 and Aβ1–42 in CR-fed compared to AL-fed
mice. Further investigation revealed that γ-secretase activity
had no involvement in the anti-amyloidogenic activity ob-
served but that α-secretase activity (which promotes the
nonamyloidogenic processing of APP) likely played a role in
theobservedbeneﬁtsofCRtreatmentinmice.Asα-secretase
cleavage of APP is known to involve the release of a soluble
and neuroprotective form of APP (sAPPα), it is possible that
CR may not only promote a non-amyloidogenic pathway in
the brain, but also may promote brain repair activities as a
result of sAPPα neurotrophic function [37].
Current therapeutic approaches to AD are aimed at pre-
venting the generation of amyloidogenic Aβ peptides, and
for this reason, β-a n dγ-secretase activities required for the
formation of Aβ peptides are central targets in the devel-
opment of therapeutic agents in AD [38]. However, it has
been diﬃcult for scientists to ﬁnd safe and selective β-a n d
γ-secretase inhibitors, as these activities are vital in the
processing of other cellular substrates [38]. Our studies col-
lectively revealed that CR dietary intervention beneﬁtted AD
mice by promoting α-secretase activity, and thereby inhibit-
ing the generation of high molecular weight Aβ peptides.
3.1. Sirtuins (SIRT1) in CR-Mediated AD Prevention. Sirtu-
ins are class III histone deacetylases (HDAC) known as silent
information regulators, which serve to catalyze deacetylation
reactions in an NAD(+)-dependent manner. Often called
“longevity” genes, sirtuins regulate important cell functions
by deacetylating histone and nonhistone targets. Activation
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aging in a variety of species and by protecting crucial tis-
sues in the body, including those in the heart and brain. In
mammalian systems, sirtuin activators protect against ax-
onal degeneration, polyglutamine toxicity, and microglia-
mediated Aβ toxicity, suggesting the potential therapeutic
value of sirtuin activation in patients with AD [39]. SIRT1
has been found to protect against microglia-dependent Aβ
toxicity by inhibiting NF-κB signaling in the brain [40].
In 2006, we reported for the ﬁrst time that promotion
of SIRT1-mediated deacetylase activity may be a mechanism
throughwhichCRinﬂuencesAD-typeamyloidneuropathol-
ogy. CR by 30% reduced carbohydrate intake was found
to prevent amyloid neuropathology in young-adult Tg2576
mice, which may have been mediated in part through mech-
anisms involving activation of mammalian SIRT1 [41]. Con-
sistent with this evidence in Tg2576 mice, we conﬁrmed
this ﬁnding in a new animal model by showing that a
similar 30% CR regimen in squirrel monkeys coincided with
a signiﬁcant reduction in Aβ1–40 and Aβ1–42 peptide content
in the brain, which inversely correlated with the elevation
of SIRT1 protein concentrations, relative to AL-fed monkeys
[42]. In view of the fact that several studies in squirrel mon-
keys have been successfully used to provide important hu-
man physiological and biological information at organism,
tissue, cellular, and molecular levels, these studies in squirrel
monkeys strongly support our hypothesis that clinically
applicable CR regimens in humans might be eﬀective in
preventing amyloid neuropathology and possibly MCI and
AD.
Collectively,ourstudiesonCRinADmiceandinsquirrel
monkeys revealed that certain experimental CR dietary regi-
mens may promote, attenuate, or even partially reverse fea-
t u r e so fA D[ 32, 41, 42]. In our studies, we found that high
caloric intake, in particular of saturated fat, promotes AD-
type β-amyloidosis and that reducing carbohydrate intake
may actually prevent it, possibly through SIRT1-mediated
response mechanisms.
4. The Role of InsulininAD
Insulin and insulin signaling have been suggested to play a
rolethepathophysiologyofAD[43,44].Inpopulation-based
studies, individuals with type 2 diabetes mellitus are at an
increased risk for cognitive impairment, dementia, and neu-
rodegeneration. Mechanisms through which diabetes pre-
sents a risk factor include glycemia, insulin resistance, oxi-
dative stress, advanced glycation endproducts, inﬂammatory
cytokines, and microvascular and macrovascular disease
[45]. The principal defect in type 2 diabetes is insulin resist-
ance, leading to insulin deﬁciency. The islet of Langerhans
(in the pancreas) in type 2 diabetes is characterized by β-cell
loss and islet amyloid derived from islet amyloid polypeptide
(IAPP) [46–48], a protein co-expressed and se-creted with
insulin by β-cells. As with Aβ peptides, IAPP spontaneously
forms into amyloid aggregates in an aqueous environment
[49]. Additionally, as with AD, the incidence of type 2 di-
abetes strongly increases with age. Borderline diabetes is also
associatedwithincreasedrisksofdementiaandAD,indepen-
dent of whether one develops diabetes in later life, and may
interact with severe systolic hypertension to multiply one’s
risk for Alzheimer’s disease [50]. These ﬁndings implicate a
close biological relationship between type 2 diabetes and AD.
In addition to complications aﬀecting the eyes, kidneys,
heart,bloodvesselsandnerves,diabetesmellitusisassociated
with damage to the central nervous system (CNS) and cog-
nitive deﬁcits [51, 52]. Impairments in learning and memory
have been documented in both types 1 and 2 diabetes. CNS
deﬁcits range from moderate to severe, depending on the
quality of glycemic control, and involve mainly verbal mem-
ory and complex information processing [53–55]. Further-
more, it has been shown that insulin aﬀects several brain
functionsincludingcognitionandmemory,andseveralstud-
ies have established links between insulin resistance, diabetes
mellitus and AD [56]. Recent evidence indicates that insulin
regulates the metabolism of Aβ and tau proteins [57–59].
It has also been suggested that desensitization of neuronal
insulin receptors and certain signaling events in AD could
lead to reduced acetylcholine levels and cerebral blood ﬂow,
resulting in chronic and increasing deﬁcits in oxidative
metabolism [60]. Additionally, insulin is known to facilitate
the hepatic clearance of plasma Aβ1–40 by intracellular trans-
location of low-density lipoprotein receptor-related protein
1 (LRP-1) to the plasma membrane in hepatocytes [61].
Alzheimer’s disease (AD) is associated with major im-
pairments in insulin and insulin-like growth factor (IGF)
gene expression and signaling in the brain, which increase
with severity of dementia and deﬁcits in energy metabolism
and acetylchoine homeostasis. This coexistence of insulin/
IGF deﬁciency and resistance in the brain suggests that AD
may represent a brain-speciﬁc form of diabetes (i.e., type
3 diabetes). This hypothesis is supported by ﬁndings from
de la Monte and colleagues [62] in an experimental animal
model in which intracerebral streptozotocin (ic-STZ) was
used to deplete brain, and not pancreatic, insulin. The ic-
STZtreatmentproducedbrain-speciﬁcinsulindepletionand
insulin resistance and was associated with progressive neu-
rodegeneration sharing many features in common with AD.
They demonstrated that early treatment with peroxisome-
proliferator activated receptor agonists can eﬀectively pre-
vent ic-STZ-induced neurodegeneration and its associated
deﬁcitsin learning and memoryand that theobserved eﬀects
were mediated by increased binding to insulin receptors,
reduced levels of oxidative stress and tau phosphorylation,
and increased choline acetyltransferase expression in the
brain, suggesting potential therapeutic eﬃcacy of insulin
sensitizing agents in AD.
4.1. Diabetogenic Diets and AD Amyloid Pathology. There is
in vitro evidence that insulin itself may signiﬁcantly promote
the generation of extracellular amyloidogenic Aβ peptides
through mechanisms that involve accelerated APP/Aβ traf-
ﬁcking from the trans-Golgi network (a major cellular site
for Aβ generation) to the plasma membrane [63]. While this
evidence tentatively suggests that abnormal carbohydrate
metabolism might play an important role in AD through
mechanisms that involve Aβ peptide generation, experimen-
tal studies also suggest that insulin resistance may promote
AD amyloid neuropathology in Tg2576 mice, possibly byInternational Journal of Alzheimer’s Disease 5
limiting Aβ degradation via competition with insulin for
degradation by the insulin-degrading enzyme (IDE) [64], a
zincmetallopeptidasethatpreferentiallycleavesproteinswith
a propensity to form β-pleated sheet-rich amyloid ﬁbrils,
such as monomeric Aβ peptides [64].
Recentevidencesuggestsaroleforinsulineveninnormal
memory function, thereby supporting the hypothesis that
insulin by itself aﬀects mechanisms related to neuronal ac-
tivity and cognitive function. Of particular interest to our
research group, chronic hyperinsulinemia and insulin resis-
tance, or reduced insulin eﬀectiveness, has been demonstrat-
ed to negatively inﬂuence memory [65, 66]. For example,
Hoyer [60] proposed that low concentrations in circulating
insulin in the CNS, along with reduced expression of insulin
receptors and subsequent altered downstream signaling in
AD, would ultimately lead to reduced levels of acetylcholine
and a corresponding decrease in cerebral blood ﬂow.
Based on this evidence, and the fact that type 2 diabetes
appears to be associated with an increased relative risk for
AD [60, 63, 65–67], we recently explored in our laboratory
the role of experimental type 2 diabetes in a Tg2576 mouse
model of AD amyloid neuropathology. We found that a
diabetogenic diet, resulting in elevated circulating levels of
insulin, promoted amyloidogenic Aβ1–40 and Aβ1–42 peptide
generation and amyloid plaque burden in the brain of
Tg2576 mice. This also corresponded with increased γ-
secretase activities and decreased IDE activities. Moreover,
the increased AD-type amyloid neuropathology also coin-
cided with increased impairments in spatial memory func-
tion [68]. Further exploration of this interrelationship be-
tween insulin resistance and brain amyloidosis revealed
a functional decrease in insulin receptor- (IR-) mediated
signal transduction in the brain, as suggested by decreased
IR β-subunit (IR-β Y1162/1163) autophosphorylation and
reducedphosphatidylinositol3(Pl3)-kinase/pS473-AKT/pro-
tein kinase- (PK-) B in these same brain samples [68]. This
study collectively suggests that diet-induced insulin resis-
tance in AD mice may signiﬁcantly promote AD-type am-
yloidosis in the brain through mechanisms involving the ele-
vation of γ-secretase activity as a result of impaired IR sig-
naling and also that type 2 diabetes may contribute to AD
amyloid pathology by attenuating the degradation of Aβ
peptide pathways associated with IDEs.
Interestingly, a later study by Li and colleagues [69]e x -
plored whether AD-type pathological changes in the brain
occur in two experimental rat models which develop type 1
and type 2 diabetes. They found accumulations of β-amyloid
and phosphor-tau in these mice and that these pathologies
were associated with neurite degeneration and neuronal loss.
Changes in the rat model of type 2 diabetes were more severe
and appeared to be associated with insulin resistance and
possibly hypercholesterolemia. Additionally, Huang and col-
leages [70] found that compared to normal mice, a mouse
model of hyperglycemia was more vulnerable to β-amyloid
oxidative stress. These ﬁndings further support the role of
insulin and insulin resistance in AD neuropathology and
provide evidence that preventing diabetic conditions may in
turn help to prevent AD dementia.
5. Hypertensionand AD
Several studies have demonstrated an association between
high blood pressure and AD [71–73]. It has been suggested
that hypertension can increase one’s risk for AD by poten-
tially causing cerebrovascular disease or changes in blood
vessel walls (which could lead to hypoperfusion, ischemia,
andhypoxia),amongotherconditions,whichcanpotentially
initiate the pathological degenerative AD process. Addition-
ally, subclinical AD has also been suggested as a risk factor
for high blood pressure; thus, similar biological mechanisms
may be involved in the pathogenesis of these two conditions
[74].
The relationship between cognitive function and anti-
hypertensive drug therapy has been investigated in several
studies of hypertensive elderly human patients. For example,
Guo and colleagues [75] found that a combination of certain
calcium channel and β-adrenergic blockers used as antihy-
pertensive agents protected elderly individuals from devel-
oping AD. Similarly, other studies have demonstrated that
certain calcium channel blockers, such as dihydropyricine
[76] and nitrendipine [77], decreased the incidence of AD
in hypertensive individuals. Further, it has also been found
that antihypertensive drugs that are K+-sparing diuretics, in
particular, reduce the risk of AD in elderly individuals with
hypertension [78]. Moreover, it was demonstrated that anti-
hypertensive agents that cross the BBB and aﬀect the rennin-
angiotensin-aldosterone system (including perindopril or
losartan), or brain calcium metabolism (like nitrendipine),
provide additional protection against cognitive decline in
addition to blood pressure control. All of these studies
suggest a neuroprotective eﬀect of certain antihypertensive
agents.
Inlightoftheseﬁndings,animalstudiesinourlaboratory
have shown that the application of certain antihypertensive
drugs can improve cognition in animal models of AD. We
conducted a high-throughput drug screening of 55 commer-
cially available antihypertensive drugs and found 7 candidate
agents that signiﬁcantly reduced AD-type Aβ accumulation
in the brains of Tg2576 mice. Of these 7 drugs, we found that
valsartan, an angiotensin receptor blocker, attenuated the
oligomerization of Aβ into high-molecular-weight (HMW)
oligomeric peptides (known to be involved in cognitive dete-
rioration) in vitro and reduced the content of soluble HMW
oligomeric Aβ in the brain in preventive studies. Addition-
ally, we also found that valsartan, delivered at a dose 2-fold
lower than the equivalent clinical dosage used in humans
forhypertension,signiﬁcantlyattenuatedthedevelopmentof
Aβ-mediated cognitive deterioration [79]. Another in vitro
study in this line of investigation revealed that the antihy-
pertensive drugs furosemide, nitrendipine, and candesartan
cilexetil prevented Aβ1–40 and Aβ1–42 oligomerization and
that furosemide in particular dissociated preaggregated
Aβ1–42 oligomers; follow-up studies revealed that short-term
treatment with furosemide in Tg2576 mice resulted in
reduced Aβ content in the brain [80]. Most recently, we have
investigated the potential beneﬁcial eﬀects of carvedilol, a
nonselective α/β-adrenergic receptor blocker used to treat
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mouse models. We found that chronic oral treatment with
carvedilol signiﬁcantly attenuated brain contents of oligo-
meric Aβ and cognitive deterioration in two mouse models
of AD (the Tg2576 model of β-amyloidosis and TgCRND8
model of tauopathy), which coincided with improvements
in neuronal transmission and the maintenance of less stable
“learning” thin dendritic spines (associated with learning
and memory functions) in the brains of these AD mice [81].
A related study in our laboratory investigated the beneﬁts
of carvedilol in AD on an electrophysiological parameter
of learning and memory, long-term potentiation (LTP), as
assessed in the TgCRND8 mouse model [82]. In this ex vivo
study, hippocampal slices from carvedilol-treated TgCRND8
mice chronically treated with carvedilol showed improved
basal neurotransmission and improved LTP, relative to slices
from nontreated TgCRND8 mice, indicating that carvedilol
improves neuroplasticity in this mouse model of AD.
Collectively, these studies suggest a clear link between
hypertensive conditions and AD and, importantly, that anti-
hypertensive agents may beneﬁt AD. In turn, these studies
also indicate that taking dietary precautions to prevent hy-
pertension may, in turn, reduce one’s risk for AD.
6.TheLinkbetweenDietaryChoicesandAD
A large area of research in the ﬁeld of neurodegeneration
has been focused on the role of speciﬁc foods and food
components in the neurodegenerative process. Luchsinger
et al. [65, 66] posited that taking nutritional supplements
alone(e.g.,carotenoidsversuscarrots)mightnotbeaseffect-
ive as whole foods in providing nutrients, perhaps because
the interaction of nutrients within whole foods or certain
dietary patterns might contribute largely to any food’s bene-
ﬁt. As an example, one study [83] demonstrated that plant-
based low-fat diets might be superior to low-fat diets con-
taining little plant-based food intake (e.g., lower consump-
tion of fruits, vegetables, nuts, etc.), even if the two diets
have identical contents of fat, protein, carbohydrates, and
cholesterol. The authors further noted that the beneﬁcial
eﬀect of low-density lipoprotein (LDL) cholesterol in one’s
diet should not be underestimated.
One food of high interest in the AD prevention ﬁeld has
been ﬁsh. For example, researchers have investigated the
beneﬁts of certain omega-3 fatty acids found in ﬁsh and ﬁsh
oils, speciﬁcally docosohexaenoic acid (DHA) and eicosa-
pentaenoic acid, which have been shown to aﬀect psychiatric
and behavioral symptoms in AD, as demonstrated in animal
studies and in human epidemiological studies [84, 85]. In
this line of research, Lim and colleagues [86] demonstrated
that DHA-enriched diets signiﬁcantly reduced AD-type
amyloid neuropathology by approximately 70%, including a
decrease in Aβ1–42 levels, compared to low-DHA or control
diets, in a mouse model of AD. Moreover, Hashimoto and
colleagues [87] studied the eﬀects of DHA on AD-type
pathology following 12 weeks of DHA administration and
found that DHA treatment led to a decreased number of
working memory errors in Aβ-infused rats in addition to
an increase in corticohippocampal DHA levels and in the
molar ratio of DHA/arachidonic acid, suggesting that DHA
treatmentattenuatedimpairedspatialcognitionandlearning
abilities. They further demonstrated that DHA suppressed
increases in levels of lipid peroxide and reactive oxygen
species in the cerebral cortex and hippocampus of these Aβ-
infused rats, which suggested that DHA may also increase
antioxidative defenses. These ﬁndings collectively demon-
strated DHA’s potential as a therapeutic agent in AD.
Another area of interest to researchers has been the ben-
eﬁts of certain plant extracts and spices in AD. In traditional
Asian medicine, various leaves, fruits, barks, roots, and so
forthhavebeenusedasagentstoimprovememoryfunctions.
In Ayurvedic medicine (a traditional system of Indian med-
icine), for example, Bacopa monnieri, Centella asiatica, With-
aniasomnifera,Glycrrhizaglabra,Acoruscalamus,andEmbli-
ca oﬃcinalis have been considered to enhance one’s memory.
Based on this notion, various laboratories have tested some
ofthesememory-enhancingcompoundsinmousemodelsof
AD. Mulberry leaf, for example, has been shown to inhibit
Aβ1–42 ﬁbril formation and protect hippocampal neurons
from Aβ1–42-induced cell death in a concentration-depend-
ent manner [88]. Additionally, in a screening of 27 herbs for
their ability to protect Aβ1–42-induced neuronal death, Cur-
cuma aromatia and Zingiber oﬃcinale (ginger) extracts were
found to most eﬀectively protect neurons. Several other
herbs were also found to be neuroprotective (such as Gink-
go biloba (Ginkgo), Polygonatum sp. (King Solomon’s seal),
Cinnamum cassia (Chinese cinnamon), and Rheum core-
anum (Korean rhubarb)), but did not exert as potent eﬀects
[89].
Ginkgo biloba extract in particular has been heavily
investigated for its use as a preventive and therapeutic agent
in AD. It has been shown to exhibit neuroprotective eﬀectsin
several mouse models [90] and improve cognitive function
in AD patients [91, 92]. Several studies have demonstrated
the mechanisms by which Ginkgo biloba extract may beneﬁt
AD. For example, it has been shown to improve age-related
memory deﬁcits and Aβ-peptide burden, act as a nitric oxide
scavenger [93, 94], and regulate APP metabolism toward the
α-secretasepathway[95].Ginkgobilobaextracthasalsobeen
shown to inhibit Aβ-induced free radical generation in a
dose-dependent manner [96]. Further, Yao and colleagues
[97] examined a speciﬁc Ginkgo biloba extract EGb761 in
relation to cholesterol and amyloidogenesis and found that
EGb761 treatment reduced APP and Aβ generation coinci-
dental with decreased levels of free circulating cholesterol
in in vivo (in rats) and in vitro studies. Moreover, Lee and
colleagues [98] investigated ginkgolides A and B for their
eﬀect on Aβ-modulated acetylcholine release from hippo-
campal brain slices and found that ginkgolide B may pro-
duce antiamnestic eﬀects by mitigating Aβ peptides’ in-
hibitory eﬀect on cholinergic transmission. These studies
have provided evidence supporting further investigation of
Ginkgo biloba extract in AD.
Another plant extract, curcumin, a polyphenolic yellow
pigment in the turmeric spice used in Indian curries and
in Indian herbal medicine, has been investigated for its po-
tential use in AD prevention and therapy. Epidemiological
studies demonstrated that the prevalence of AD in individu-
als 70–79 years of age is 4.4-fold less in the India comparedInternational Journal of Alzheimer’s Disease 7
to the U.S. [99]. The curcumin compound (1,7-bis(4-hy-
droxy-3-methoxyphenyl)-1,6heptadiene-2,5dione)hasbeen
shown to be neuroprotective against Aβ toxicity in vitro
[100],antiamyloidogenic[101,102],andcapableofreducing
brain amyloid load and plaque burden [103]. Spectropho-
tometric studies have suggested that curcumin binds to the
more readily redox-reactive metals Cu and Fe, but does not
bind to Zn, and, in turn, acts as an antioxidant by chelating
the redox active metal ions in the body [104]. Lim and
colleagues [105] found that dietary curcumin treatment in
AD mice signiﬁcantly lowered levels of oxidized proteins,
interleukin-1 β (a proinﬂammatory cytokine elevated in
these mice), and insoluble and soluble Aβ in the brain and
reduced amyloid plaque burden by 43%–50%.
Several other spices have been investigated for their role
in AD. For example, aged garlic extract has been shown in
vitro to suppress the generation of reactive oxygen species,
which are known to be involved in apoptosis as a result of
Aβ-mediated neurotoxicity [106], suggesting that garlic
compounds may enhance antioxidant defenses in the brain.
Additional in vitro evidence demonstrated that garlic treat-
ment inhibits caspase-3 in a dose-dependent manner, which
indicates that garlic may inhibit apoptotic neuronal death in
the brain [107]. Another spice of interest to researchers as
beenCrocussativus,o rs a ﬀron, dueto its unusuallypolar car-
otenoid components. Notable, certain saﬀron extracts have
been shown to inhibit Aβ ﬁbrillogenesis [108]. Further
research on these extracts may illuminate precise mecha-
nisms of action on AD neuropathology and their potential
as preventive or therapeutic agents in AD.
6.1. Fruit Juices and Wine. Polyphenols, the most abundant
dietary antioxidants, have been heavily investigated for their
ability to provide neuroprotection against oxidative dam-
age in the brain. One study that propagated research on
polyphenols in AD, conducted by Dai and colleagues [109],
revealed that long-term fruit juice consumption can reduce
one’s risk for AD. The investigators suggested that the neu-
roprotective eﬀects of fruit juices can be enhanced by con-
suming a combination of juices that are rich in phenolic
compounds, which include juices derived from purple
grapes, grapefruit, cranberries, and apples.
Several studies have examined the eﬀects of certain fruit
juices and extracts on AD. For example, apple juice was
shown to prevent Aβ-induced oxidative damage in vitro
[110], and blueberry treatment has been found to reverse the
eﬀects of aging on motor behavior and neuronal signaling
in animal models [111], possibly through mechanisms in-
volving signal transduction, neuronal communication, and
enhancement of hippocampal plasticity [112, 113]. More-
over, treatment with antioxidant-rich pomegranate juice has
beenshowntoreduceAβ1–42 contentandamyloiddeposition
in the hippocampus by approximately 50% in mice. A study
conducted by Mullen and colleagues [114] examined 13
diﬀerent fruit juices and reported that purple grape juice
contained the highest number of individual phenolic com-
pounds in addition to the highest concentration of total phe-
nolics. The main components found in purple grape juice,
accountingfor93%ofthetotalphenolicconent,wereﬂavan-
3-ols, anthocyanins, and hydroxycinnamates. White grape
juice, on the contrary, containing mainly hydroxycinna-
mates, had the lowest phenolic content of the juices exam-
ined.
Resveratrol is a naturally occurring polyphenol, found
in the skin of grapes and red wine as a result of exposure
to fungi or bacteria, which has been investigated for its abil-
ity to neuroprotect. Resveratrol has been demonstrated to
maintain cell viability, exert antioxidant activity, exert prote-
asome-dependent antiamyloidogenic activity, and attenuate
Aβ-induced cytotoxicity in PC12 cells in vitro [115–117].
Importantly, resveratrol is also understood to activate the
expression of sirtuins, often referred to as the “longevity
gene,” in yeast [118] and in mammalian animal models of
neurodegeneration [119, 120]—this resveratrol-induced sir-
tuin activation has been shown to promote neuroprotective
activities against neuronal apoptosis. However, given recent
evidence suggesting that resveratrol may not directly activate
sirtuins [121], it is not quite clear if sirtuin activation
plays a role in resveratrol’s observed beneﬁts in AD-type
neuropathology. Further research will certainly illuminate
resveratrol’s bioactivity and the mechanisms through which
it beneﬁts AD.
Several studies have suggested that moderate red wine
consumption reduces the incidence of AD clinical dementia
[65, 66, 115, 122–124] and may even beneﬁt the course
of AD [125]. Derived from red grapes, red wine is rich in
antioxidants and holds neuroprotective properties. Studies
in our laboratory, using an AD mouse model, examined
whether moderate consumption of the red wine cabernet
sauvignon (the most polyphenol-rich red wine, likely due
to increased inclusion of grape skins) reduces AD-type
neuropathology and cognitive deterioration. We found that
cabernet sauvignon treatment was capable of attenuating
AD-type cognitive deterioration and Aβ neuropathology by
mechanisms involving nonamyloidogenic processing of APP,
ultimately inhibiting Aβ generation [126, 127].
6.2. Grape Seed Polyphenolic Extract. Another area of investi-
gation of high interest in the AD ﬁeld has been the potential
beneﬁcial role of grape seed polyphenolic extract (GSPE) in
attenuating AD-type neuropathology and cognitive impair-
ments. Studies in our laboratory have investigated a speciﬁc
GSPE (MegaNatural), which is comprised primarily of cat-
echin and epicatechin in monomeric, oligomeric, and poly-
meric forms, is readily absorbed through the intestinal mu-
cosua due to modiﬁcation of the constituent polyphenols in
its preparation and has been demonstrated to be safe in ani-
mal models [128–131] and in humans with pre-hypertensive
conditions [132]. In an initial investigation in a mouse
model of AD [129], mice were treated for 5 months with
200mg/kg/dayGSPEindrinkingwater(equivalentto1g/day
in humans, according to Food and Drug Administration
criteria for converting drug dosages across species), after
which in vitro and in vitro assessments were conducted at
6 (for behavior) and 10 (for neuropathology) months. In
vitro studies revealed that GSPE prevented Aβ peptides from
aggregating into high molecular weight (HMW) oligomers,
and in vivo studies showed that GSPE treatment significantly8 International Journal of Alzheimer’s Disease
reduced Aβ1–40 and Aβ1–42 peptide and HMW Aβ oligomer
levelsandamyloidplaqueburdeninthebrain,relativetoage-
and gender-matched water-treated mice. Moreover, GSPE-
treated mice also performed signiﬁcantly better tests of cog-
nitive function compared to age- and gender-matched water
treated mice. A follow-up mechanistic study [130]i n v e s t i -
gated in vitro GSPE’s ability to alter the assembly of Aβ1–40
and Aβ1–42 oligomers and Aβ-induced cytotoxicity in Aβ-
treated PC12 cells; these studies revealed that GSPE blocked
Aβ protoﬁbril formation, preprotoﬁbrillar oligomerization,
and the structure transition from initial coil to α-helix/β-
sheet. Additionally, GSPE exerted protective activities in
assays of Aβ-induced cytoxicity (prior to peptide assembly,
following assembly, and just prior to peptide addition in
cells). These studies collectively suggest a neuroprotective
and possibly therapeutic role of GSPE in AD-type Aβ neu-
ropathology and cognitive deterioration.
To follow this line of work, we also investigated in vitro
the potential beneﬁcial role of GSPE on AD-type tau neu-
ropathology [133], another major hallmark of AD. Using
an in vitro model system, we found that GSPE treatment
signiﬁcantly inhibited the aggregation of tau peptides into
ﬁlaments and was also capable of dissociating preformed tau
aggregates. This ﬁnding suggests that GSPE treatment may
attenuate deposits of tau aggregates in the AD brain.
In light of our evidence that GSPE was capable of at-
tenuating Aβ and tau pathology, we next explored GSPE
bioavailability [131] to further assess its potential as an AD
treatment. We found that acute oral administration of GSPE
in Sprague Dawley rats led to detectable contents of catechin,
epicatechin and their metabolites in the brain. Following re-
peated GSPE exposure, we detected accumulations of cat-
echin, epicatechin, and gallic acid and their metabolites in
the blood and similarly, catechin and epicatechin and their
metabolites in the brain.
These studies, which demonstrate GSPE’s ability to at-
tenuate AD-type Aβ pathology in vivo and in vitro and tau
pathology in vitro, combined with its demonstrated safety
and bioavailability, support the continued development of
GSPE as a treatment for Aβ- and tau-mediated neurodegen-
eration and cognitive impairments.
7. Conclusions andFutureTrends
Collectively, epidemiological and experimental research has
demonstrated that dietary choices can play a key role in the
prevention of AD and dementia. For example, much of the
research described here suggest that preventing and manag-
ing conditions such as diabetes, hypertension, obesity, and
heart disease may in turn prevent the onset of pathological
aging and dementia. Research from our laboratory and
others has demonstrated that reducing calorie intake can
help prevent AD and similarly, given the demonstrated rela-
tionship between diabetogenic conditions and AD, that pre-
venting diabetes (perhaps by limiting one’s glucose intake)
may also decrease one’s risk for AD. Moreover, studies have
demonstratedthatconsumingfoodsthatarerichinpolyphe-
nols, such as blueberries or grapes, may also prevent AD and
cognitive deterioration, perhaps through their antioxidant
and antiamyloidogenic activities. Based on the evidence de-
scribed, it seems possible that in the near future, we may
be able to utilize our knowledge of AD prevention through
dietary changes and work toward intensive dietary interven-
tion(s) that might be capable of preventing or treating AD.
However, when reviewing this body of scientiﬁc litera-
ture, one must understand that this area of research is still
in its infancy, and further research must be conducted before
making any dietary recommendations to the general public
for preventing neurodegenerative conditions of aging. For
example, conditions such as AD are chronic and have a
long latency period, and conducting clinical trials for dietary
interventions under such circumstances, over long enough
periods of time and on large enough samples to draw ac-
curate and repeatable conclusions, would be a highly com-
plex endeavor. Moreover, any dietary recommendations
made toward this aim must always be incorporated into a
general healthy diet. Future research on dietary lifestyles
and their role in the prevention or treatment of dementia
will certainly elucidate which diets and foods are capable of
exertingneuroprotectiveactivities,inwhatquantities,andby
what mechanism(s) of action.
The current medical model for preventing and treating
neurodegenerative conditions such as AD lacks a “whole or-
ganism” approach. For example, the onset of AD is likely a
result of genomic and proteomic factors, but also psychoso-
cial and lifestyle factors, such as nutrient intake or levels of
stress. Today, Medicare and other insurers and individuals
will pay billions of dollars for various surgical and medical
procedures to treat chronic conditions (such as heart disease
or diabetes), and yet they pay very little for integrative and
preventive medicine approaches (such as alterations in diet)
that can prevent or reverse many chronic conditions. By
further investigating the role that dietary choices may play in
AD and other dementias and diseases of aging, we will work
towardtheutilizationofanintegrativeapproachtomedicine,
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